Regenxbio Inc

Stock Chart, Company Information, and Scan Results

$14.87(as of Jan 13, 3:40 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Regenxbio Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$14.87
Ticker SymbolRGNX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees353
CountyUSA
Market Cap$738.6M
EBIDTA-139.2M
10-Day Moving Average14.39
P/E Ratio-4.38
20-Day Moving Average14.24
Forward P/E Ratio0.00
50-Day Moving Average12.99
Earnings per Share-3.46
200-Day Moving Average10.03
Profit Margin-208.32%
RSI59.85
Shares Outstanding50.6M
ATR0.96
52-Week High15.84
Volume1,003,135
52-Week Low5.04
Most Recent Support Level14.55
Book Value161.5M
Most Recent Resistance Level15.80
P/B Ratio4.83
Upper Keltner16.39
P/S Ratio4.83
Lower Keltner12.09
Debt-to-Equity Ratio16.39
Next Earnings Date03/03/2026
Cash Surplus-65.8M
Next Ex-Dividend DateUnknown

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Regenxbio Inc In Our Stock Scanner

As of Jan 13, 2026
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cup and HandleScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.